Review
doi: 10.1016/j.lpm.2015.02.019.
Epub 2015 May 23.
Risks of treatments and long-term outcomes of systemic ANCA-associated vasculitis
Affiliations
- PMID: 26009242
- DOI: 10.1016/j.lpm.2015.02.019
Item in Clipboard
Review
Risks of treatments and long-term outcomes of systemic ANCA-associated vasculitis
Presse Med.
2015 Jun.
Abstract
Patients with ANCA-associated vasculitis (AAV) have an increased risk of premature death and organ failure. Treatment strategies with immune-suppressive drugs need to balance disease control and prevention of relapse against the risk of side effects in particular infection and malignancy. The longer-term outcome of patients with AAV who participated in several randomised controlled trials has been published in recent years. The results of these and other newer studies will be the focus of this review.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.
Similar articles
-
[The role of rituximab in the treatment of ANCA-associated systemic vasculitis].G Ital Nefrol. 2011 Sep-Oct;28(5):474-88. G Ital Nefrol. 2011. PMID: 22028261 Review. Italian.
-
Trends in Long-Term Outcomes Among Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Renal Disease.Arthritis Rheumatol. 2016 Jul;68(7):1711-20. doi: 10.1002/art.39614. Arthritis Rheumatol. 2016. PMID: 26814428 Free PMC article.
-
[Rituximab for the treatment of ANCA associated vasculitis: the future today?].Reumatol Clin. 2011 Dec;7 Suppl 3:S41-6. doi: 10.1016/j.reuma.2011.10.006. Epub 2011 Nov 23. Reumatol Clin. 2011. PMID: 22115869 Review. Spanish.
-
Update on the treatment of ANCA associated vasculitis.Presse Med. 2015 Jun;44(6 Pt 2):e241-9. doi: 10.1016/j.lpm.2015.04.008. Epub 2015 May 26. Presse Med. 2015. PMID: 26021670 Review.
-
L42. Morbidity in patients with ANCA-associated vasculitis.Presse Med. 2013 Apr;42(4 Pt 2):612-6. doi: 10.1016/j.lpm.2013.01.040. Epub 2013 Mar 5. Presse Med. 2013. PMID: 23465300 Review. No abstract available.
Cited by
-
Patient and physician perspectives on the impact of health-related quality of life in Mexican patients with ANCA-associated vasculitis.Rheumatol Int. 2018 Apr;38(4):631-640. doi: 10.1007/s00296-017-3904-1. Epub 2017 Dec 15. Rheumatol Int. 2018. PMID: 29247347
-
Long-term Clinical Course of Antineutrophil Cytoplasmic Antibody-associated Vasculitis Patients off Maintenance Therapy.Cureus. 2018 Mar 26;10(3):e2372. doi: 10.7759/cureus.2372. Cureus. 2018. PMID: 29805941 Free PMC article.
-
Health-related quality of life in patients with ANCA vasculitides compared to rheumatoid arthritis: a cross-sectional comparative study.Rheumatology (Oxford). 2024 Feb 1;63(2):399-406. doi: 10.1093/rheumatology/kead214. Rheumatology (Oxford). 2024. PMID: 37171857 Free PMC article.
-
Cathepsin C inhibition reduces neutrophil serine protease activity and improves activated neutrophil-mediated disorders.Nat Commun. 2024 Aug 22;15(1):6519. doi: 10.1038/s41467-024-50747-6. Nat Commun. 2024. PMID: 39174512 Free PMC article.
-
Bruton's tyrosine kinase is a possible therapeutic target in microscopic polyangiitis.Arthritis Res Ther. 2023 Nov 6;25(1):215. doi: 10.1186/s13075-023-03201-9. Arthritis Res Ther. 2023. PMID: 37932784 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
